Answers are grounded in this paper and cite their sources.
The efficacy of zimeldine in preventing depressive episodes in recurrent major depressive disorders was evaluated in a randomized, placebo-controlled study involving 40 patients. The intended study period was 18 months. The results showed zimeldine to be significantly more effective than placebo, both in terms of preventing recurrence (t-test: P less than 0.001) and the withdrawal rate (Cox's test: P less than 0.01). Adverse symptoms for zimeldine did not differ from placebo. There were no noteworthy changes in clinical chemistry, blood pressure, ECG and pulse rate.
No takes yet. Share an insight, caveat, or question.
Kerstin Björk (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: